Trial Profile
A Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Burixafor; Granulocyte colony-stimulating factors
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 16 Jan 2019 Status changed from active, no longer recruiting to discontinued.
- 28 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 28 Jul 2017 Status changed from recruiting to active, no longer recruiting.